Azopt 1% Ophthalmic Suspension — Competitive Intelligence Brief

Azopt 1% Ophthalmic Suspension (Azopt 1% Ophthalmic Suspension) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Carbonic anhydrase inhibitor. Area: Ophthalmology.

phase 3 Carbonic anhydrase inhibitor Carbonic anhydrase II Ophthalmology Small molecule

Target snapshot

Azopt 1% Ophthalmic Suspension (Azopt 1% Ophthalmic Suspension) — Padagis LLC. Azopt is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye to lower intraocular pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Azopt 1% Ophthalmic Suspension TARGET	Azopt 1% Ophthalmic Suspension	Padagis LLC	phase 3	Carbonic anhydrase inhibitor	Carbonic anhydrase II
Azopt	BRINZOLAMIDE	Novartis	marketed	Carbonic Anhydrase Inhibitor [EPC]	carbonic anhydrase II	1998-01-01
tafluprost and dorzolamide/timolol	tafluprost and dorzolamide/timolol	Aristotle University Of Thessaloniki	marketed	Prostaglandin analogue / carbonic anhydrase inhibitor / beta-blocker combination	Prostaglandin F receptor (FP receptor), carbonic anhydrase II, beta-1 and beta-2 adrenergic receptors
dorzolamide/timolol maleate fixed combination	dorzolamide/timolol maleate fixed combination	Pharmaceutical Research Network	marketed	Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination	Carbonic anhydrase II; Beta-adrenergic receptors (β1 and β2)
Cosopt PF 2%-0.5% Ophthalmic Solution	Cosopt PF 2%-0.5% Ophthalmic Solution	Prairie Eye Center	marketed	Fixed-dose combination of carbonic anhydrase inhibitor and beta-blocker	Carbonic anhydrase II (dorzolamide component); beta-adrenergic receptors (timolol component)
Latanoprost, Dorzolamide	Latanoprost, Dorzolamide	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	marketed	Prostaglandin analog + Carbonic anhydrase inhibitor combination	Prostaglandin F receptor (FP receptor) and Carbonic anhydrase II
Brinzolamide/Brimonidine FC	Brinzolamide/Brimonidine FC	University Hospital of Patras	marketed	Carbonic anhydrase inhibitor / Alpha-2 adrenergic agonist combination	Carbonic anhydrase II; Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Carbonic anhydrase inhibitor class)

1. Bausch & Lomb Incorporated · 2 drugs in this class
2. Actavis Inc. · 2 drugs in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Merck Sharp & Dohme LLC · 1 drug in this class
5. National University Hospital, Singapore · 1 drug in this class
6. Padagis LLC · 1 drug in this class
7. Rabin Medical Center · 1 drug in this class
8. Shahid Beheshti University of Medical Sciences · 1 drug in this class
9. Sun Pharmaceutical Industries Limited · 1 drug in this class
10. University Health Network, Toronto · 1 drug in this class